ERBB2 and breast cancer: PI3K pathway alterations are additionally targetable through the newest approved pan-AKT inhibitor capivasertib (111, 112), which is currently being evaluated in combination with T-DXd for HER2-low BC in the phase III DESTINY-Breast08 trial (113).